These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15599853)

  • 21. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE
    J Clin Oncol; 2006 Jun; 24(17):2659-65. PubMed ID: 16763280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma.
    Wang WM; Zhao ZL; Ma SR; Yu GT; Liu B; Zhang L; Zhang WF; Kulkarni AB; Sun ZJ; Zhao YF
    PLoS One; 2015; 10(2):e0119723. PubMed ID: 25723392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecularly targeted therapies in head and neck cancers.
    Sawicki M; Szudy A; Szczyrek M; Krawczyk P; Klatka J
    Otolaryngol Pol; 2012; 66(5):307-12. PubMed ID: 23036118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nuclear localization signal-enhanced RNA interference of EZH2 and Oct4 in the eradication of head and neck squamous cell carcinoma-derived cancer stem cells.
    Lo WL; Chien Y; Chiou GY; Tseng LM; Hsu HS; Chang YL; Lu KH; Chien CS; Wang ML; Chen YW; Huang PI; Hu FW; Yu CC; Chu PY; Chiou SH
    Biomaterials; 2012 May; 33(14):3693-709. PubMed ID: 22361100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular targeted therapy of head and neck cancer: review and clinical development challenges.
    Le Tourneau C; Faivre S; Siu LL
    Eur J Cancer; 2007 Nov; 43(17):2457-66. PubMed ID: 17904355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor as a therapeutic target in head and neck cancer.
    Bonner JA; De Los Santos J; Waksal HW; Needle MN; Trummel HQ; Raisch KP
    Semin Radiat Oncol; 2002 Jul; 12(3 Suppl 2):11-20. PubMed ID: 12174340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in the management of squamous cell carcinoma of the head and neck.
    Kim KB; Khuri FR; Shin DM
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):99-110. PubMed ID: 12113140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines.
    Song JI; Lango MN; Hwang JD; Drenning SD; Zeng Q; Lamph WW; Grandis JR
    Cancer Res; 2001 Aug; 61(15):5919-25. PubMed ID: 11479234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoxia inducible factor as a cancer drug target.
    Welsh SJ; Powis G
    Curr Cancer Drug Targets; 2003 Dec; 3(6):391-405. PubMed ID: 14683498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted therapy: A novel approach in head and neck cancer.
    Christy AW; Bojan A
    Indian J Dent Res; 2013; 24(2):261-6. PubMed ID: 23965459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
    Zhang X; Chen ZG; Choe MS; Lin Y; Sun SY; Wieand HS; Shin HJ; Chen A; Khuri FR; Shin DM
    Clin Cancer Res; 2005 Sep; 11(17):6261-9. PubMed ID: 16144930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
    Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
    Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting angiogenesis in head and neck cancer.
    Saba NF; Shin DM; Khuri FR
    Curr Cancer Drug Targets; 2007 Nov; 7(7):643-9. PubMed ID: 18045069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents.
    Harrington KJ; Kazi R; Bhide SA; Newbold K; Nutting CM
    Indian J Cancer; 2010; 47(3):248-59. PubMed ID: 20587899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN).
    Hambek M; Baghi M; Baumaun H; Strebhardt K; Adunka O; Gstöttner W; Knecht R
    Anticancer Res; 2005; 25(3B):1871-5. PubMed ID: 16158919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway.
    Tan C; de Noronha RG; Roecker AJ; Pyrzynska B; Khwaja F; Zhang Z; Zhang H; Teng Q; Nicholson AC; Giannakakou P; Zhou W; Olson JJ; Pereira MM; Nicolaou KC; Van Meir EG
    Cancer Res; 2005 Jan; 65(2):605-12. PubMed ID: 15695405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer.
    Koukourakis MI; Giatromanolaki A; Sivridis E; Pastorek J; Karapantzos I; Gatter KC; Harris AL;
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):67-71. PubMed ID: 15093900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dysregulation of hypoxia inducible factor-1alpha in head and neck squamous cell carcinoma cell lines correlates with invasive potential.
    Cohen NA; Lai SY; Ziober AF; Ziober BL
    Laryngoscope; 2004 Mar; 114(3):418-23. PubMed ID: 15091212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
    Smilek P; Neuwirthova J; Jarkovsky J; Dusek L; Rottenberg J; Kostrica R; Srovnal J; Hajduch M; Drabek J; Klozar J
    Neoplasma; 2012; 59(5):508-15. PubMed ID: 22668015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.